Literature DB >> 30939629

Hypertriglyceridaemia predicts subsequent long-term risk of cardiovascular events in Chinese adults: 23-year follow-up of the Daqing Diabetes Study.

Jinping Wang1, Xiaoxia Shen2, Siyao He2, Yali An2, Qiuhong Gong2, Hui Li1, Bo Zhang3, Ying Shuai3, Yanyan Chen2, Yinghua Hu1, Guangwei Li2,3.   

Abstract

BACKGROUND: Limited information is available on the long-term risk of cardiovascular disease (CVD) associated with hypertriglyceridaemia (HTG) in the Chinese population. We estimated this risk over a 23-year period in participants recruited from among those included in the Da Qing Diabetes Study.
METHODS: A total of 833 Chinese adults including 379 with normal glucose levels and 454 with hyperglycaemia were identified by their oral glucose tolerance in 1986 in Da Qing, China. CVD outcomes were monitored until 2009. Thirty-four percent (280/833) of the participants had HTG, which was defined as a fasting plasma triglyceride (TG) level ≥ 1.7 mmol/L, at the baseline time point.
RESULTS: Over the 23-yearfollow-up period, 149 subjects in the HTG group and 190 subjects in the non-HTG group (NTG group) experienced their first CVD event, including fatal or nonfatal myocardial infarction (MI) and stroke. The age and sex-adjusted annual incidence of the first CVD event per 1000 person-years was 30.23 for the HTG group vs 18.68 for the NTG group. The corresponding rates for MI and stroke were 7.71 vs 3.89 and 19.55 vs 13.98, respectively. After adjusting for confounders, the HTG group had a 28% higher risk of the first CVD event than the NTG group. This association was significant among only the subjects with a serum cholesterol level > 5.7 mmol/L and those with diabetes or impaired glucose tolerance (IGT).
CONCLUSION: HGT predicted a substantially higher subsequent long-term risk of the first CVD event in Chinese adults, especially in those with hypercholesterolaemia and hyperglycaemia.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  cardiovascular; diabetes; hypertriglyceridaemia

Mesh:

Substances:

Year:  2019        PMID: 30939629     DOI: 10.1002/dmrr.3163

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  3 in total

Review 1.  GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?

Authors:  Maurício Reis Pedrosa; Denise Reis Franco; Hannah Waisberg Gieremek; Camila Maia Vidal; Fernanda Bronzeri; Alexia de Cassia Rocha; Luis Gabriel de Carvalho Cara; Sofia Lenzi Fogo; Freddy Goldberg Eliaschewitz
Journal:  Curr Atheroscler Rep       Date:  2022-08-31       Impact factor: 5.967

2.  Treatment of Chinese Patients with Hypertriglyceridemia with a Pharmaceutical-Grade Preparation of Highly Purified Omega-3 Polyunsaturated Fatty Acid Ethyl Esters: Main Results of a Randomized, Double-Blind, Controlled Trial.

Authors:  Litong Qi; Qiuling Zhang; Zeqi Zheng; Zhaohui Pei; Hong Mao; Tingbo Jiang; Dmitri Kazei; Elke Kahler; Yong Huo
Journal:  Vasc Health Risk Manag       Date:  2021-09-15

3.  Lower Baseline Serum Triglyceride Levels Are Associated With Higher Decrease in Body Mass Index After Laparoscopy Sleeve Gastrectomy Among Obese Patients.

Authors:  Xiu Huang; Guifang Li; Bei Xu; Junyi Zhang; Xingchun Wang; Xiaoyun Cheng; Muthukumaran Jayachandran; Yueye Huang; Shen Qu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-22       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.